A Phase 1, Open-label, Fixed-sequence, 2-period Study In Healthy Volunteers To Investigate The Effect Of Multiple Doses Of Rifampin On Single Dose Glasdegib (Pf-04449913) Plasma Pharmacokinetics
Phase of Trial: Phase I
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Glasdegib (Primary) ; Rifampicin
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 28 Feb 2018 Results published in the British Journal of Clinical Pharmacology
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 24 Jun 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.